002412 汉森制药
已收盘 02-26 15:00:00
资讯
新帖
简况
汉森制药(002412)1月30日股东户数2.23万户,较上期减少7.65%
证券之星 · 02-26 17:16
汉森制药(002412)1月30日股东户数2.23万户,较上期减少7.65%
汉森制药:截至2026年1月30日,公司含信用账户合并股东名册的股东总数为
证券之星 · 02-24 16:09
汉森制药:截至2026年1月30日,公司含信用账户合并股东名册的股东总数为
汉森制药:截至2026年1月30日,公司含信用账户合并股东名册的股东总数为
证券之星 · 02-12
汉森制药:截至2026年1月30日,公司含信用账户合并股东名册的股东总数为
股市必读:汉森制药2月6日涨停收盘,收盘价7.59元
证券之星 · 02-09
股市必读:汉森制药2月6日涨停收盘,收盘价7.59元
行业重磅政策助力,汉森制药股价涨停
证券之星 · 02-06
行业重磅政策助力,汉森制药股价涨停
异动快报:汉森制药(002412)2月6日9点34分触及涨停板
证券之星 · 02-06
异动快报:汉森制药(002412)2月6日9点34分触及涨停板
股市必读:汉森制药(002412)股东户数2.23万户,较上期减少7.65%
证券之星 · 02-05
股市必读:汉森制药(002412)股东户数2.23万户,较上期减少7.65%
汉森制药:公司的主导产品已全部修订完毕
证券之星 · 02-04
汉森制药:公司的主导产品已全部修订完毕
汉森制药:公司暂无相关药物
证券之星 · 01-30
汉森制药:公司暂无相关药物
股市必读:汉森制药(002412)1月23日董秘有最新回复
证券之星 · 01-26
股市必读:汉森制药(002412)1月23日董秘有最新回复
汉森制药:百贝益肺胶囊用于肺阴不足咳嗽
证券之星 · 01-23
汉森制药:百贝益肺胶囊用于肺阴不足咳嗽
汉森制药:公司始终坚守中成药主业
证券之星 · 01-21
汉森制药:公司始终坚守中成药主业
股市必读:汉森制药(002412)1月20日董秘有最新回复
证券之星 · 01-21
股市必读:汉森制药(002412)1月20日董秘有最新回复
股市必读:汉森制药(002412)1月8日董秘有最新回复
证券之星 · 01-09
股市必读:汉森制药(002412)1月8日董秘有最新回复
汉森制药:截至2025年11月28日股东总数为24145人
证券之星 · 2025-12-22
汉森制药:截至2025年11月28日股东总数为24145人
汉森制药:坚守中成药主业做大做强
证券之星 · 2025-12-19
汉森制药:坚守中成药主业做大做强
汉森制药:截至2025年11月28日股东总数为24145人
证券之星 · 2025-12-15
汉森制药:截至2025年11月28日股东总数为24145人
汉森制药:该事项有助于公司实现整合资源、提升产能利用及扩大普药销售
证券之星 · 2025-12-10
汉森制药:该事项有助于公司实现整合资源、提升产能利用及扩大普药销售
汉森制药:截至2025年11月28日股东总数为24145人
证券之星 · 2025-12-02
汉森制药:截至2025年11月28日股东总数为24145人
汉森制药:苁蓉颗粒处于工艺中试放大阶段
证券之星 · 2025-11-25
汉森制药:苁蓉颗粒处于工艺中试放大阶段
加载更多
公司概况
公司名称:
湖南汉森制药股份有限公司
所属行业:
医药制造业
上市日期:
2010-05-25
主营业务:
湖南汉森制药股份有限公司的主营业务是生产中药制剂、化学药。公司的主要产品是四磨汤口服液、缩泉胶囊、银杏叶胶囊、天麻醒脑胶囊、愈伤灵胶囊、百贝益肺胶囊、利胆止痛胶囊、胃肠灵胶囊、藿香正气水、玉竹膏、通关藤胶囊、参七心疏胶囊、感冒清热颗粒、人工牛黄甲硝唑胶囊、氢溴酸右美沙芬颗粒、复方氨酚烷胺片、卡托普利片、甲硝唑片、碳酸氢钠片、碘海醇注射液、碘帕醇注射液、泛影葡胺注射液。
发行价格:
35.80
{"stockData":{"symbol":"002412","market":"SZ","secType":"STK","nameCN":"汉森制药","latestPrice":7.43,"timestamp":1772089410000,"preClose":7.47,"halted":0,"volume":22051710,"delay":0,"changeRate":-0.0054,"floatShares":498000000,"shares":503000000,"eps":0.3419,"marketStatus":"已收盘","change":-0.04,"latestTime":"02-26 15:00:00","open":7.46,"high":7.56,"low":7.37,"amount":164000000,"amplitude":0.0254,"askPrice":7.44,"askSize":502,"bidPrice":7.43,"bidSize":162,"shortable":0,"etf":0,"ttmEps":0.3419,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1772155800000},"marketStatusCode":5,"adr":0,"adjPreClose":7.47,"symbolType":"stock","openAndCloseTimeList":[[1772069400000,1772076600000],[1772082000000,1772089200000]],"highLimit":8.22,"lowLimit":6.72,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":503200000,"isCdr":false,"pbRate":1.66,"roa":"--","peRate":21.7315,"roe":"3.69%","epsLYR":0.4377,"committee":0.007064,"marketValue":3739000000,"turnoverRate":0.0443,"status":1,"floatMarketCap":3699000000},"requestUrl":"/m/hq/s/002412","defaultTab":"news","newsList":[{"id":"2614016206","title":"汉森制药(002412)1月30日股东户数2.23万户,较上期减少7.65%","url":"https://stock-news.laohu8.com/highlight/detail?id=2614016206","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614016206?lang=zh_cn&edition=full","pubTime":"2026-02-26 17:16","pubTimestamp":1772097415,"startTime":"0","endTime":"0","summary":"证券之星消息,近日汉森制药披露,截至2026年1月30日公司股东户数为2.23万户,较11月28日减少1848.0户,减幅为7.65%。在中药行业个股中,汉森制药股东户数低于行业平均水平,截至1月30日,中药行业平均股东户数为5.25万户。从股价来看,2025年11月28日至2026年1月30日,汉森制药区间跌幅为1.46%,在此期间股东户数减少1848.0户,减幅为7.65%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022600026073.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0039","BK0239","002412"],"gpt_icon":0},{"id":"2613793481","title":"汉森制药:截至2026年1月30日,公司含信用账户合并股东名册的股东总数为","url":"https://stock-news.laohu8.com/highlight/detail?id=2613793481","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613793481?lang=zh_cn&edition=full","pubTime":"2026-02-24 16:09","pubTimestamp":1771920583,"startTime":"0","endTime":"0","summary":"证券之星消息,汉森制药(002412)02月24日在投资者关系平台上答复投资者关心的问题。投资者提问:请问最新一期公司的股东人数是多少?汉森制药回复:尊敬的投资者您好,公司可在互动易平台回复非定期报告时点的月末股东人数,截至2026年1月30日,公司含信用账户合并股东名册的股东总数为:22297人。感谢您对公司的关注!以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022400028892.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0039","002412","BK0028"],"gpt_icon":0},{"id":"2610928749","title":"汉森制药:截至2026年1月30日,公司含信用账户合并股东名册的股东总数为","url":"https://stock-news.laohu8.com/highlight/detail?id=2610928749","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610928749?lang=zh_cn&edition=full","pubTime":"2026-02-12 11:34","pubTimestamp":1770867266,"startTime":"0","endTime":"0","summary":"证券之星消息,汉森制药(002412)02月11日在投资者关系平台上答复投资者关心的问题。投资者提问:尊敬的董秘你好,请问截止至2026年2月10日收盘公司股东人数为多少,谢谢!汉森制药回复:尊敬的投资者您好,公司可在互动易平台回复非定期报告时点的月末股东人数,截至2026年1月30日,公司含信用账户合并股东名册的股东总数为:22297人。感谢您对公司的关注!以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026021200014408.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0039","BK0028","002412"],"gpt_icon":0},{"id":"2610433572","title":"股市必读:汉森制药2月6日涨停收盘,收盘价7.59元","url":"https://stock-news.laohu8.com/highlight/detail?id=2610433572","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610433572?lang=zh_cn&edition=full","pubTime":"2026-02-09 01:08","pubTimestamp":1770570493,"startTime":"0","endTime":"0","summary":"截至2026年2月6日收盘,汉森制药报收于7.59元,上涨10.0%,涨停,换手率15.94%,成交量79.34万手,成交额5.97亿元。交易信息汇总汉森制药2月6日涨停收盘,收盘价7.59元。该股于9点34分涨停,盘中11次打开涨停,截至收盘封单资金为1792.12万元,占其流通市值的0.47%。资金流向2月6日主力资金净流入827.95万元,游资资金净流入266.86万元,散户资金净流出1094.81万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020900000564.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0039","002412","BK0028","BK0239"],"gpt_icon":0},{"id":"2609537973","title":"行业重磅政策助力,汉森制药股价涨停","url":"https://stock-news.laohu8.com/highlight/detail?id=2609537973","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609537973?lang=zh_cn&edition=full","pubTime":"2026-02-06 10:24","pubTimestamp":1770344657,"startTime":"0","endTime":"0","summary":"2月6日,中药板块集体大涨。个股方面,汉森制药股价实现涨停。消息面上值得关注的是工业和信息化部等八部门日前联合印发《中药工业高质量发展实施方案》。《方案》明确,到2030年,中药工业全产业链协同发展体系初步形成,重点中药原料持续稳定供应能力进一步增强,数智化、绿色化水平明显提升,一批关键技术取得突破,产业协同创新水平显著提高。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/SS2026020600011972.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0039","BK0028","BK0239","002412"],"gpt_icon":0},{"id":"2609532646","title":"异动快报:汉森制药(002412)2月6日9点34分触及涨停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2609532646","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609532646?lang=zh_cn&edition=full","pubTime":"2026-02-06 09:36","pubTimestamp":1770341789,"startTime":"0","endTime":"0","summary":"证券之星2月6日盘中消息,9点34分汉森制药(002412)触及涨停板。其所属行业中药目前上涨。领涨股为达仁堂。该股为中药,流感,医药概念热股,当日中药概念上涨2.01%,流感概念上涨0.87%,医药概念上涨0.71%。2月5日的资金流向数据方面,主力资金净流入87.11万元,占总成交额1.29%,游资资金净流出478.55万元,占总成交额7.07%,散户资金净流入391.44万元,占总成交额5.78%。近5日资金流向一览见下表:汉森制药主要指标及行业内排名如下:以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020600009161.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0039","002412","BK0239","BK0028"],"gpt_icon":0},{"id":"2609392532","title":"股市必读:汉森制药(002412)股东户数2.23万户,较上期减少7.65%","url":"https://stock-news.laohu8.com/highlight/detail?id=2609392532","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609392532?lang=zh_cn&edition=full","pubTime":"2026-02-05 02:28","pubTimestamp":1770229692,"startTime":"0","endTime":"0","summary":"截至2026年2月4日收盘,汉森制药报收于6.84元,上涨1.18%,换手率1.39%,成交量6.94万手,成交额4716.86万元。当日关注点来自交易信息汇总:2月4日主力资金净流出179.93万元,散户资金净流入281.2万元。股本股东变化股东户数变动近日汉森制药披露,截至2026年1月30日公司股东户数为2.23万户,较11月28日减少1848.0户,减幅为7.65%。户均持股数量由上期的2.08万股增加至2.26万股,户均持股市值为15.21万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020500001406.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0039","002412","BK0028"],"gpt_icon":0},{"id":"2608038733","title":"汉森制药:公司的主导产品已全部修订完毕","url":"https://stock-news.laohu8.com/highlight/detail?id=2608038733","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608038733?lang=zh_cn&edition=full","pubTime":"2026-02-04 09:06","pubTimestamp":1770167184,"startTime":"0","endTime":"0","summary":"证券之星消息,汉森制药02月03日在投资者关系平台上答复投资者关心的问题。这意味着,国内现存约5.7万个中成药有效批准文号中,超70%存在安全信息标注问题的批文将面临淘汰。公司的主导产品已全部修订完毕,其他产品已按相关要求在有序推进。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020400007769.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0039","002412","BK0239","BK0028"],"gpt_icon":0},{"id":"2607431063","title":"汉森制药:公司暂无相关药物","url":"https://stock-news.laohu8.com/highlight/detail?id=2607431063","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607431063?lang=zh_cn&edition=full","pubTime":"2026-01-30 08:54","pubTimestamp":1769734450,"startTime":"0","endTime":"0","summary":"证券之星消息,汉森制药(002412)01月29日在投资者关系平台上答复投资者关心的问题。投资者提问:印度东部西孟加拉邦近期出现尼帕病毒的感染病例 ,贵司有专业防范方法和药物吗?汉森制药回复:尊敬的投资者您好,公司暂无相关药物。感谢您的关注!以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026013000007746.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002412","BK0028","BK0039","BK0239"],"gpt_icon":0},{"id":"2606265038","title":"股市必读:汉森制药(002412)1月23日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2606265038","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606265038?lang=zh_cn&edition=full","pubTime":"2026-01-26 03:44","pubTimestamp":1769370253,"startTime":"0","endTime":"0","summary":"截至2026年1月23日收盘,汉森制药报收于6.9元,上涨0.15%,换手率1.04%,成交量5.2万手,成交额3578.02万元。投资者: 董秘您好,请问公司到1月20日的股东人数,谢谢董秘: 投资者您好,公司可在互动易平台回复非定期报告时点的月末股东人数,截至2025年12月31日公司的股东人数,公司将在2025年年度报告中披露,后续可关注公司在指定信息披露媒体及巨潮资讯网披露的相关公告。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012600001643.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002412","BK0028","BK0039"],"gpt_icon":0},{"id":"2605695420","title":"汉森制药:百贝益肺胶囊用于肺阴不足咳嗽","url":"https://stock-news.laohu8.com/highlight/detail?id=2605695420","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605695420?lang=zh_cn&edition=full","pubTime":"2026-01-23 16:24","pubTimestamp":1769156676,"startTime":"0","endTime":"0","summary":"证券之星消息,汉森制药(002412)01月23日在投资者关系平台上答复投资者关心的问题。投资者提问:你好,天眼查贵公司全资子公司云南永孜堂制药有限公司发明了一种治疗阴虚痰瘀证的组合物及其制备方法和应用,请问具体是治疗哪方面的,是创新药吗,谢谢汉森制药回复:尊敬的投资者您好,百贝益肺胶囊的主要功能为滋阴润肺,止咳化痰。用于治疗肺阴不足咳嗽;慢性支气管炎咳嗽。具体产品信息您可查阅公司官网,药品使用谨遵医嘱。感谢您的关注!以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012300023582.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0039","BK0239","002412"],"gpt_icon":0},{"id":"2605102596","title":"汉森制药:公司始终坚守中成药主业","url":"https://stock-news.laohu8.com/highlight/detail?id=2605102596","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605102596?lang=zh_cn&edition=full","pubTime":"2026-01-21 20:51","pubTimestamp":1768999875,"startTime":"0","endTime":"0","summary":"证券之星消息,汉森制药01月20日在投资者关系平台上答复投资者关心的问题。请问如何改进,贵公司管理层是否积极面对和解决不足之处,也真诚希望汉森制药未来发展越来越好,谢谢汉森制药回复:尊敬的投资者您好,公司始终坚守中成药主业、延伸大健康产业和融合金融产业的发展战略。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012100038881.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0039","002412","BK0028"],"gpt_icon":0},{"id":"2605414517","title":"股市必读:汉森制药(002412)1月20日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2605414517","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605414517?lang=zh_cn&edition=full","pubTime":"2026-01-21 03:21","pubTimestamp":1768936863,"startTime":"0","endTime":"0","summary":"截至2026年1月20日收盘,汉森制药报收于6.87元,上涨0.88%,换手率1.28%,成交量6.39万手,成交额4375.73万元。当日关注点来自交易信息汇总:1月20日主力资金净流入265.46万元,显示主力对汉森制药短期走势持积极态度。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012100002583.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0039","002412","BK0239","BK0028"],"gpt_icon":0},{"id":"2602539469","title":"股市必读:汉森制药(002412)1月8日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2602539469","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602539469?lang=zh_cn&edition=full","pubTime":"2026-01-09 01:58","pubTimestamp":1767895090,"startTime":"0","endTime":"0","summary":"截至2026年1月8日收盘,汉森制药报收于6.69元,上涨2.45%,换手率2.01%,成交量10.03万手,成交额6662.22万元。董秘最新回复投资者: 同属湖南的中成药公司方盛制药2024年又特别分红,每年中期也分红,而贵公司汉森制药几年不见分红一次,股价又不涨,如何体现贵公司所说的已持续稳定的业绩汇报投资者,难道只是口头说说?当日关注点来自:1月8日主力资金净流入668.21万元,显示主力对汉森制药短期走势持积极态度。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010900001209.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0039","002412","BK0239","BK0028"],"gpt_icon":0},{"id":"2593889174","title":"汉森制药:截至2025年11月28日股东总数为24145人","url":"https://stock-news.laohu8.com/highlight/detail?id=2593889174","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593889174?lang=zh_cn&edition=full","pubTime":"2025-12-22 16:54","pubTimestamp":1766393661,"startTime":"0","endTime":"0","summary":"证券之星消息,汉森制药(002412)12月22日在投资者关系平台上答复投资者关心的问题。投资者提问:尊敬的董秘您好,请问公司到十二月二十日的股东人数,谢谢汉森制药回复:尊敬的投资者您好,公司可在互动易平台回复非定期报告时点的月末股东人数,截至2025年11月28日,公司含信用账户合并股东名册的股东总数为:24145人。感谢您对公司的关注!以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122200019844.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002412","BK0039","BK0028"],"gpt_icon":0},{"id":"2592164248","title":"汉森制药:坚守中成药主业做大做强","url":"https://stock-news.laohu8.com/highlight/detail?id=2592164248","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592164248?lang=zh_cn&edition=full","pubTime":"2025-12-19 20:52","pubTimestamp":1766148720,"startTime":"0","endTime":"0","summary":"证券之星消息,汉森制药(002412)12月18日在投资者关系平台上答复投资者关心的问题。投资者提问:请问贵公司有考虑加大中药研究和发扬光大中药吗?谢谢汉森制药回复:尊敬的投资者您好,公司“一体两翼”发展战略中,明确了坚守中成药主业,立足中成药主业进行产业延伸和融合,通过内生增长和外延发展“双轮驱动”,做大做强中成药主业。感谢您的关注!以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121900036453.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0028","002412","BK0039"],"gpt_icon":0},{"id":"2591616226","title":"汉森制药:截至2025年11月28日股东总数为24145人","url":"https://stock-news.laohu8.com/highlight/detail?id=2591616226","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591616226?lang=zh_cn&edition=full","pubTime":"2025-12-15 16:09","pubTimestamp":1765786149,"startTime":"0","endTime":"0","summary":"证券之星消息,汉森制药(002412)12月15日在投资者关系平台上答复投资者关心的问题。投资者提问:请问截止2025年12月10日股东人数是多少?汉森制药回复:尊敬的投资者您好,公司可在互动易平台回复非定期报告时点的月末股东人数,截至2025年11月28日,公司含信用账户合并股东名册的股东总数为:24145人。感谢您对公司的关注!以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121500015157.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0039","002412","BK0239","BK0028"],"gpt_icon":0},{"id":"2590375842","title":"汉森制药:该事项有助于公司实现整合资源、提升产能利用及扩大普药销售","url":"https://stock-news.laohu8.com/highlight/detail?id=2590375842","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590375842?lang=zh_cn&edition=full","pubTime":"2025-12-10 08:51","pubTimestamp":1765327871,"startTime":"0","endTime":"0","summary":"投资者提问:据报道91届药交会上,汉森制药携省级联盟集采产品四磨汤口服液、银杏叶胶囊,基药产品缩泉胶囊、感冒清热颗粒,特色产品天麻醒脑胶囊、百贝益肺胶囊、参七心疏胶囊参展,重磅推出汉森普药贴牌直招,请问贵公司推出汉森普药贴牌直招是对公司来说是利好吗,如何看待后续业务合规性,谢谢汉森制药回复:尊敬的投资者您好,该事项有助于公司实现整合资源、提升产能利用及扩大普药销售。公司将坚持合规生产与经营。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121000005113.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0039","BK0239","002412","BK0028"],"gpt_icon":0},{"id":"2588803353","title":"汉森制药:截至2025年11月28日股东总数为24145人","url":"https://stock-news.laohu8.com/highlight/detail?id=2588803353","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588803353?lang=zh_cn&edition=full","pubTime":"2025-12-02 16:12","pubTimestamp":1764663144,"startTime":"0","endTime":"0","summary":"证券之星消息,汉森制药(002412)12月02日在投资者关系平台上答复投资者关心的问题。投资者提问:董秘,您好!请问公司截至11月30日的股东人数是多少?谢谢汉森制药回复:投资者您好,截至2025年11月28日,公司含信用账户合并股东名册的股东总数为:24145人。感谢您对公司的关注!以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120200019544.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0039","BK0028","BK0239","002412"],"gpt_icon":0},{"id":"2586385411","title":"汉森制药:苁蓉颗粒处于工艺中试放大阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2586385411","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586385411?lang=zh_cn&edition=full","pubTime":"2025-11-25 08:33","pubTimestamp":1764030785,"startTime":"0","endTime":"0","summary":"证券之星消息,汉森制药(002412)11月24日在投资者关系平台上答复投资者关心的问题。投资者提问:请问贵公司在研发方面有取得进展成果吗?谢谢汉森制药回复:尊敬的投资者您好,公司在研发方面,中药新药苁蓉颗粒正处于工艺中试放大研究阶段。后续如有重大进展情况,将严格遵守信息披露相关规定。感谢您的关注!以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112500004320.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0239","002412","BK0039"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1772132597702,"stockEarnings":[{"period":"1week","weight":0.0027},{"period":"1month","weight":0.0706},{"period":"3month","weight":0.0863},{"period":"6month","weight":0.1073},{"period":"1year","weight":0.2121},{"period":"ytd","weight":0.1591}],"compareEarnings":[{"period":"1week","weight":0.0158},{"period":"1month","weight":0.0016},{"period":"3month","weight":0.0664},{"period":"6month","weight":0.0748},{"period":"1year","weight":0.2267},{"period":"ytd","weight":0.0448}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"湖南汉森制药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"22297人(较上一季度减少7.65%)","perCapita":"22327股","listingDate":"2010-05-25","address":"湖南省益阳市赫山区银城大道2688号","registeredCapital":"50320万元","survey":" 湖南汉森制药股份有限公司的主营业务是生产中药制剂、化学药。公司的主要产品是四磨汤口服液、缩泉胶囊、银杏叶胶囊、天麻醒脑胶囊、愈伤灵胶囊、百贝益肺胶囊、利胆止痛胶囊、胃肠灵胶囊、藿香正气水、玉竹膏、通关藤胶囊、参七心疏胶囊、感冒清热颗粒、人工牛黄甲硝唑胶囊、氢溴酸右美沙芬颗粒、复方氨酚烷胺片、卡托普利片、甲硝唑片、碳酸氢钠片、碘海醇注射液、碘帕醇注射液、泛影葡胺注射液。","listedPrice":35.8},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"汉森制药(002412)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供汉森制药(002412)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"汉森制药,002412,汉森制药股票,汉森制药股票老虎,汉森制药股票老虎国际,汉森制药行情,汉森制药股票行情,汉森制药股价,汉森制药股市,汉森制药股票价格,汉森制药股票交易,汉森制药股票购买,汉森制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"汉森制药(002412)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供汉森制药(002412)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}